LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
A spin-out of the University of Geneva and Barcelona's Vall d’Hebron Research Institute, the company is focused on protein biomarkers for brain injury.
The researchers argued that fecal immunochemical test could be used as "rule-in" test for patients with ambiguous symptoms.
The researchers detected an average of 56 possible environmental organic acids present in each subject and confirmed the presence of six of them.
The researchers have prospectively validated a disposable cartridge-based microfluidic assay by obtaining results using fine-needle aspirates in 40 patients.
The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.
The firm has begun validating its porphyrin molecule marker test for use with flow cytometry at four sites and anticipates adding four, or more, to complete the validation.
By applying the plasmonic patch as a final step in assay development, diagnostic test developers will be able to increase fluorescence intensity onehundred-fold.
The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.